- Brand names:
- Pharmaceutical Company:
- Condition/Indication: T-cell lymphoma
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1985KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 2984KB)
Brentuximab vedotin – March 2021
Brentuximab vedotin: Powder for I.V. infusion 50 mg; Adcetris®
Last updated
2 July 2021